![Drew Moghanaki: It’s reassuring to see longitudinal data aligning with the recommendations we provide patients with stage I NSCLC deciding between surgery and SBRT during usual care](https://oncodaily.com/pub/uploads/2023/09/Drew-f-e1712249408620-1280x1038.jpg)
Photo taken from Drew Moghanaki/X
Apr 4, 2024, 13:39
Drew Moghanaki: It’s reassuring to see longitudinal data aligning with the recommendations we provide patients with stage I NSCLC deciding between surgery and SBRT during usual care
Drew Moghanaki, Lung Cancer Specialist at UCLA Health Jonsson Cancer Center, shared a post on X:
“It’s reassuring to see longitudinal data aligning with the recommendations we provide patients with stage I NSCLC deciding between surgery and SBRT during usual care. As we say, ‘It’s a bumpier road in the beginning after surgery, yet patients have similar QOL a year later regardless of which upfront treatment they received.’ ”
Additional information.
Source: Drew Moghanaki/X
Aug 16, 2024, 20:23